Yakup Ergün· @dr_yakupergun · X·· 23 小时前评分70
正文 · 原文
#ESMO26 | KEYNOTE-B49 – Phase III
In PD-L1 CPS ≥1 HR+/HER2− mBC, pembrolizumab + chemotherapy:
PFS: 6.7 vs 6.0 months (HR 0.74)
OS: 21.0 vs 22.2 months (HR 1.04)
CPS ≥10: PFS HR 0.59; OS HR 0.82.
Although the PFS curves converge early, a signal of durable benefit emerges in a small subset of patients.
However, no OS benefit was demonstrated, and toxicity increased (1.8% G5 TRAE).
100 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org#ESMO26 | KEYNOTE-B49 In patients with PD-L1 CPS ≥1, HR+/HER2− mBC previously treated with ET, pembro + chemo was compared with chemo - PFS: 6.7 vs 6.0 mo (HR 0.74) - OS: 21.0 vs 22.2 mo (HR 1.04) - CPS ≥10: PFS HR 0.59 I’m curious to see the subgroup analyses presented at ESMO. However, in the ADC era, this modest PFS benefit without an OS advantage has little clinical relevance to me. Evaluating immunotherapy in combination with ADCs or after ADC treatment may be more rational in today's treatment landscape.在 X 查看被引用的帖子
来源：Yakup Ergün · x.com